Summary
Multiple dosing and safety/efficacy-related claims conflict with or are unsupported by the provided FDA label excerpts (notably: PsA/AS dosing options with 150 mg loading and possible escalation; incorrect ERA/HS pediatric dosing timing; claims that symptom-based changes are not allowed; and unsupported assertions about infection risk being dose-related).
Category Scores
Accurate Statements
For plaque psoriasis, Cosentyx 300 mg (two 150 mg subcutaneous injections) at Weeks 0, 1, 2, 3, and 4, then every 4 weeks.
Label 2.3: 300 mg at Weeks 0,1,2,3,4 and every 4 weeks thereafter; each 300 mg dose may be given as two 150 mg injections.
After loading, adults with non-radiographic axial spondyloarthritis are dosed with Cosentyx 300 mg every 4 weeks.
Unsupported by provided excerpts: label 2.8 describes 150 mg maintenance (with or without loading) for nr-axSpA; no 300 mg q4w regimen for nr-axSpA is stated in provided text.
Unsupported Statements
Cosentyx dosage cannot be adjusted based on symptom improvement.
Provided label excerpts describe dose escalation being considered in some adult indications (PsA/AS) and HS escalation. The label text does not support a blanket statement that no symptom-based adjustment is possible.
Guidelines from the FDA and EMA emphasize adherence to labeled dosing schedules for Cosentyx to maintain efficacy.
Not supported by provided labeling excerpts.
For non-responders to Cosentyx (about 10-20% in trials), switching biologics rather than adjusting Cosentyx is an option mentioned.
No such non-responder percentage, and no label excerpt supports this management strategy.
Persistent symptoms prompt efficacy assessments at week 12-16, and no Cosentyx dose escalation is approved.
Provided label excerpts do not mention week 12–16 assessment timing nor support a blanket 'no dose escalation'.
No phase 3 trial arms tested Cosentyx dose reductions for responders.
Not supported by provided labeling excerpts.
Overdosing Cosentyx increases infections without added benefit.
Label 10 states that in overdosing, monitor for signs/symptoms and provide symptomatic treatment; it does not state infection risk 'without added benefit'.
Phase 3 trials report 70-80% PASI 75 response in psoriasis at week 12 with standard Cosentyx dosing.
No PASI 75 percentages are included in the provided label excerpts.
PASI 75 response in psoriasis decreases if Cosentyx dosing is interrupted.
No label excerpt provided with this specific interruption/decline statement.
Early withdrawal for lack of efficacy occurred in less than 5% in the cited trial description for Cosentyx.
No such numeric discontinuation rate is included in the provided label excerpts.
Contradictions
High
AI Statement
For adults with psoriatic arthritis, Cosentyx is dosed at 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, and 4, then every 4 weeks.
Label Reference
Label 2.4: Adult PsA subcutaneous dosing includes 150 mg with loading (Weeks 0-4, then every 4 weeks) and suggests considering increasing to 300 mg every 4 weeks if active PsA continues; provided label excerpt does not state 300 mg with loading at Weeks 0-4 then q4w as a default regimen.
High
AI Statement
For adults with ankylosing spondylitis, Cosentyx is dosed at 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, and 4, then every 4 weeks.
Label Reference
Label 2.6: Adult AS recommended dosage is 150 mg with loading at Weeks 0-4 and every 4 weeks thereafter; consider increasing to 300 mg every 4 weeks if active AS continues. The provided label excerpt does not support 300 mg loading as standard.
High
AI Statement
For children with enthesitis-related arthritis, Cosentyx uses a 75 mg dose weekly for 4 weeks, then every 4 weeks.
Label Reference
Label 2.9: Pediatric ERA weight-based dosing at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter (not '75 mg weekly for 4 weeks'). Also dosing is 75 mg for ≥15 kg and <50 kg and 150 mg for ≥50 kg.
Moderate
AI Statement
For pediatric enthesitis-related arthritis (age ≥ 2 years), Cosentyx dosing is 75 mg every 4 weeks after loading.
Label Reference
Label 2.9 specifies ERA pediatric patients aged 4 years and older (not ≥2 years). It also gives loading at Weeks 0-4 and then every 4 weeks thereafter; '75 mg every 4 weeks after loading' is not explicitly supported without the weight-based eligibility and age threshold.
Low
AI Statement
For pediatric enthesitis-related arthritis with weight > 50 kg, Cosentyx dosing is 150 mg every 4 weeks after loading.
Label Reference
Label 2.9 uses ≥50 kg (not 'weight > 50 kg') and specifies dosing at Weeks 0-4 and every 4 weeks thereafter; the label excerpts also indicate age 4 years and older. The exact conditional phrasing 'weight > 50 kg' is not supported as written.
Low
AI Statement
For moderate-to-severe hidradenitis suppurativa, Cosentyx is dosed at 300 mg weekly for 4 weeks, then every 4 weeks.
Label Reference
Label 2.10: Adult HS recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter (weekly during Weeks 0-4 is consistent in timing, but phrasing 'weekly for 4 weeks' omits that there are 5 weekly injections at Weeks 0-4).
High
AI Statement
Maintenance dosing for Cosentyx stays fixed regardless of response.
Label Reference
Label 2.4 and 2.6 and 2.10: The label describes considering increasing dosage to 300 mg every 4 weeks for active PsA/AS and considering increasing to 300 mg every 2 weeks for inadequate HS response. This contradicts 'stays fixed regardless of response.'
High
AI Statement
No condition allows symptom-based changes to Cosentyx dosing.
Label Reference
Label 2.4: 'If a patient continues to have active PsA, consider increasing the dosage to 300 mg every 4 weeks.' Label 2.6: 'If a patient continues to have active AS, consider increasing...' Label 2.10: 'If an adult patient does not adequately respond, consider increasing...' These are symptom/activity-based considerations.
Moderate
AI Statement
Dosing accounts for body weight in children but remains fixed in adults for Cosentyx.
Label Reference
Label 2.4 and 2.6 and 2.10 indicate adult dose escalation may be considered based on active disease/inadequate response; thus dosing is not always fixed in adults.
High
AI Statement
After loading, adults with non-radiographic axial spondyloarthritis are dosed with Cosentyx 300 mg every 4 weeks.
Label Reference
Label 2.8: Adult nr-axSpA recommended dosage is 150 mg with loading (Weeks 0-4 then every 4 weeks) or 150 mg every 4 weeks without loading. No 300 mg q4w regimen is provided in the excerpt.
Important Omissions
For multiple indications (PsA and AS), the label includes option of 150 mg with loading and consideration of increasing to 300 mg every 4 weeks if active disease continues; the AI claims omit these labeling dose pathways and escalation criteria.
Importance:
High
For pediatric ERA, the label specifies age threshold (≥4 years) and weight-based dosing thresholds (≥15 kg and <50 kg vs ≥50 kg). Several pediatric claims omit or misstate these.
Importance:
High
For adult HS, the label specifies an option to increase to 300 mg every 2 weeks for inadequate response; the AI does not mention this escalation pathway.
Importance:
Moderate
For PsO and other subcutaneous uses, label includes administration instructions (subcutaneous devices use, IV only by HCP and only certain indications). The AI claims do not address administration instructions at all.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Incorrect and overly rigid dosing assertions (e.g., PsA/AS loading at 300 mg; nr-axSpA 300 mg q4w; pediatric ERA regimen/timing/age) could lead to materially different dosing from labeling. Claims about dose changes being universally disallowed conflict with label statements about considering dose increases based on disease activity/response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several major dosing regimens and eligibility criteria are misstated or conflict with the provided FDA label excerpts (especially PsA, AS, nr-axSpA, and pediatric ERA dosing/timing/age/weight), and multiple statements incorrectly claim dosing cannot be adjusted based on response.
Suggested Improvement
Replace the asserted regimens with the label-supported dosing by indication (including 150 mg vs 300 mg options and label-described considerations for dose increases), correct pediatric ERA eligibility (age ≥4 years) and weight-based dosing thresholds, and remove unsupported efficacy/PASI and trial-percentage assertions not present in the provided label excerpts.